Search Results - "Moum, Bjorn A."

Ankylosing Spondylitis and Axial Spondyloarthritis in Patients With Long-term Inflammatory Bowel Disease: Results From 20 Years of Follow-up in the IBSEN Study by Ossum, Alvilde M, Palm, Øyvind, Lunder, Aida Kapic, Cvancarova, Milada, Banitalebi, Hasan, Negård, Anne, Høie, Ole, Henriksen, Magne, Moum, Bjørn A, Høivik, Marte Lie

“…Abstract Background Patients with inflammatory bowel disease [IBD] often suffer from rheumatic manifestations, including inflammatory back disorders. The…”
Get full text

Clinical course and prognosis in ulcerative colitis: results from population-based and observational studies by Monstad, Iril, Hovde, Oistein, Solberg, Inger Camilla, A Moum, Bjørn

“…The clinical course of ulcerative colitis (UC) may range from a quiescent course with prolonged periods of remission to fulminant disease requiring intensive…”
Get full text

High faecal calprotectin levels in intestinal tuberculosis are associated with granulomas in intestinal biopsies by Larsson, Geir, Shenoy, Kotacherry Thrivikrama, Ramasubramanian, Ramalingom, Thayumanavan, Lakshmikanthan, Balakumaran, Leena Kondarappassery, Bjune, Gunnar A., Moum, Bjørn A.

“…Abstract Background: The diagnosis of intestinal tuberculosis (ITB) is sometimes difficult to establish and requires endoscopic investigation with biopsies for…”
Get full text

Mucosal Healing in Inflammatory Bowel Disease: Results From a Norwegian Population-Based Cohort by Frøslie, Kathrine Frey, Jahnsen, Jørgen, Moum, Bjørn A, Vatn, Morten H

“…Background & Aims: Mucosal healing (MH) in inflammatory bowel disease may be an important sign of efficacy of treatment and a prognostic marker of long-term…”
Get full text

Faecal calprotectin levels differentiate intestinal from pulmonary tuberculosis: An observational study from Southern India by Larsson, Geir, Shenoy, Koticherry Thrivikrama, Ramasubramanian, Ramalingom, Thayumanavan, Lakshmikanthan, Balakumaran, Leena Kondarappassery, Bjune, Gunnar A, Moum, Bjørn A

“…Background Current methods to establish the diagnosis of intestinal tuberculosis are inadequate. Objectives We aimed to determine the clinical features of…”
Get full text

Analysis of DNA Methylation at Specific Loci in Stool Samples Detects Colorectal Cancer and High-Grade Dysplasia in Patients With Inflammatory Bowel Disease by Kisiel, John B., Klepp, Pasquale, Allawi, Hatim T., Taylor, William R., Giakoumopoulos, Maria, Sander, Tamara, Yab, Tracy C., Moum, Bjorn A., Lidgard, Graham P., Brackmann, Stephan, Mahoney, Douglas W., Roseth, Arne, Ahlquist, David A.

“…Patients with inflammatory bowel diseases (IBDs), including ulcerative colitis and Crohn’s disease, are at increased risk for colorectal cancer (CRC). Analyses…”
Get full text

Combining Anti-TNF-α and Vedolizumab in the Treatment of Inflammatory Bowel Disease: A Case Series by Buer, Lydia C T, Høivik, Marte L, Warren, David J, Medhus, Asle W, Moum, Bjørn A

“…Abstract Background Anti-tumor necrosis factor α (anti-TNF-α) is important in the treatment of inflammatory bowel disease, but some patients experience only a…”
Get full text

Switching from intravenous to subcutaneous vedolizumab maintenance treatment in patients with inflammatory bowel disease followed by therapeutic drug monitoring by Wiken, Thea H., Høivik, Marte L., Buer, Lydia, Warren, David J., Bolstad, Nils, Moum, Bjørn A., Anisdahl, Karoline, Småstuen, Milada C., Medhus, Asle W.

“…Vedolizumab (VDZ) for subcutaneous (SC) administration has recently become available. We aimed to assess feasibility, safety and clinical outcome when…”
Get full text

Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study by Hovde, Øistein, Høivik, Marte Lie, Henriksen, Magne, Solberg, Inger Camilla, Småstuen, Milada Cvancarova, Moum, Bjørn A

“…Whether patients with inflammatory bowel diseases [IBDs] have increased risk of developing cancer has been debated. The aims of the study were to determine the…”
Get full text

Switching from Remicade® to Remsima® is well Tolerated and Feasible: A Prospective, Open-label Study by Buer, Lydia C T, Moum, Bjørn A, Cvancarova, Milada, Warren, David J, Medhus, Asle W, Høivik, Marte Lie

“…A biosimilar version of infliximab [CT-P13/Remsima®] recently entered the European market. The clinical data on its use in inflammatory bowel disease [IBD] are…”
Get full text

Chronic fatigue is more prevalent in patients with inflammatory bowel disease than in healthy controls by Jelsness‐Jørgensen, Lars‐Petter, Bernklev, Tomm, Henriksen, Magne, Torp, Roald, Moum, Bjørn A.

“…Background: Fatigue is a common symptom in chronic disease. Few studies, however, have focused on fatigue related to inflammatory bowel disease (IBD). The aim…”
Get full text

Switching from originator to biosimilar infliximab - real world data of a prospective 18 months follow-up of a single-centre IBD population by Høivik, Marte L., Buer, Lydia C. T., Cvancarova, Milada, Warren, David J., Bolstad, Nils, Moum, Bjørn A., Medhus, Asle W.

“…Background and aims: Long-term data regarding switching from originator infliximab to biosimilar CT-P13 are sparse. Concerns about increased immunogenicity…”
Get full text

Mortality and causes of death in Crohn's disease: results from 20 years of follow-up in the IBSEN study by Hovde, Øistein, Kempski-Monstad, Iril, Småstuen, Milada Cvancarova, Solberg, Inger Camilla, Henriksen, Magne, Jahnsen, Jørgen, Stray, Njål, Moum, Bjørn A

“…Population-based studies have shown a slightly decreased life expectancy in patients with Crohn's disease (CD). The primary aim of the present study was to…”
Get more information

Real world data on effectiveness, safety and therapeutic drug monitoring of vedolizumab in patients with inflammatory bowel disease. A single center cohort by Buer, Lydia C. T., Moum, Bjørn A., Cvancarova, Milada, Warren, David J., Bolstad, Nils, Medhus, Asle W., Høivik, Marte L.

“…Background and aims: The efficacy of vedolizumab (VDZ) has been demonstrated in clinical trials. The aim of this report is to evaluate the long-term…”
Get full text

Real-life chromoendoscopy for dysplasia surveillance in ulcerative colitis by Klepp, Pasquale, Tollisen, Anita, Røseth, Arne, Cvancarova Småstuen, Milada, Andersen, Solveig N, Vatn, Morten, Moum, Bjørn A, Brackmann, Stephan

“…To evaluate the use of chromoendoscopy for surveillance of ulcerative colitis in a real-life community hospital setting. Patients with extensive ulcerative…”
Get full text

Multi-target stool DNA test in the surveillance of inflammatory bowel disease: a cross-sectional cohort study by Klepp, Pasquale, Kisiel, John B., Småstuen, Milada Cvancarova, Røseth, Arne, Andersen, Solveig N., Vatn, Morten H., Ahlquist, David A., Moum, Bjørn A., Brackmann, Stephan

“…Background and aim: Colonoscopic surveillance is recommended in patients with longstanding inflammatory bowel disease (IBD) as they are at increased risk of…”
Get full text

Subcutaneous Vedolizumab Treatment in a Real-World Inflammatory Bowel Disease Cohort Switched From Intravenous Vedolizumab: Eighteen-Month Prospective Follow-up Study by Wiken, Thea H, Høivik, Marte L, Anisdahl, Karoline, Buer, Lydia, Warren, David J, Bolstad, Nils, Hagen, Milada, Moum, Bjørn A, Medhus, Asle W

“…Vedolizumab has since 2021 been available as a subcutaneous formulation. We aimed to assess 18-month drug persistence and possible predictive factors…”
Get full text

Mortality and Causes of Death in Ulcerative Colitis: Results from 20 Years of Follow-up in the IBSEN Study by Hovde, Øistein, Småstuen, Milada C, Høivik, Marte L, Bernklev, Tomm, Huppertz-Hauss, Gert, Høie, Ole, Jahnsen, Jørgen, Stray, Njaal, Henriksen, Magne, Solberg, Inger C, Moum, Bjørn A

“…The best way to obtain knowledge about the natural history, including mortality, of ulcerative colitis (UC) is to conduct a longitudinal, population-based,…”
Get full text

Epidemiology and clinical course of Crohn's disease: results from observational studies by Hovde, Øistein, Moum, Bjørn A

“…The authors review the clinical outcome in patients with Crohn's disease (CD) based on studies describing the natural course of the disease. Population-based…”
Get full text

Malignancies in patients with inflammatory bowel disease: Results from 20 years of follow-up in the IBSEN study by Hovde, Øistein, Høivik, Marte Lie, Henriksen, Magne, Solberg, Inger Camilla, Småstuen, Milada Cvancarova, Moum, Bjørn A

“…Whether patients with inflammatory bowel diseases (IBDs) have increased risk of developing cancer has been debated. The aims of the study were to determine the…”
Get full text